London Asthma Diagnostics Study
- Disease/Condition
- Asthma
- Drug/Device/Intervention
- Oscillometry with reversibility testing
- Study type
- Observational
- Intervention type
- diagnostic test
- Primary sponsor
- Imperial College London
- Location
- London,London,Nottingham, United Kingdom
- Phase
- N/A
- Start date
- Jun 01, 2024
- End date
- Jul 01, 2026
- Enrollment
- 225 participants
To evaluate the diagnostic accuracy (sensitivity, specificity) of a combination of oscillometry ± reversibility, spirometry ± reversibility and FeNO
The goal of this trial is to learn if the addition of oscillometry with reversibility testing
 increases diagnostic accuracy in adult asthma diagnosis, when added to current standard of
 care tests: spirometry with reversibility testing and Fractional Exhaled Nitric Oxide (FeNO).
 The main question it aims to answer is:
 
 - Does oscillometry with reversibility testing increase diagnostic accuracy in detection of
 asthma in adults when added to spirometry with reversibility and FeNO?
 
 Researchers will evaluate the diagnostic accuracy of this approach with the reference
 standard, which is a clinically adjudicated diagnosis of asthma by two respiratory clinicians
 based on history and investigation results.
 
 Participants will
 
 - Undergo oscillometry testing alongside their routine asthma investigations within their
 scheduled clinic visit
 
 - Optionally participate in our sub-studies on new breath and nasal swab tests for asthma
 
 - Optionally participate in our qualitative substudy on patients views and attitudes to
 asthma testing and oscillometry
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06383130
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06383130 through Pure Global AI's free database. This phase not specified trial is sponsored by Imperial College London and is currently Not yet recruiting. The study focuses on Asthma. Target enrollment is 225 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.